2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3392 Safety and efficacy of lomonitinib in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)

Colin Vale, MD, William Blum, MD2, Shivani Handa, MD3, Joshua F. Zeidner, MD4, Emily Curran, MD5, Shaun Fleming, MBBS (Hons), PhD6, Genevieve Douglas, MD7, Sergei Voloshin, MD8, Brian Ledwith, PhD9, Fraser Pickersgill, PhD10, Ekaterina Dokukina, MD, PhD11, Ruben Karapetian, PhD12, Erin Hertlein, PhD13, Ola A. Elgamal, PhD,BSc14, Alexei Pushechnikov, PhD15, Natalya Chernova, MD16, Dong-Yeop Shin, MD17, Yaoyu Hsieh, MD18, Carolyn S. Grove, MBBS, PhD, FRACP, FRCPA19, Nikolay Savchuk, PhD20, Iain Dukes, DPhil21, Amy Burd, PhD22, John Byrd, MD23, Evgenii Mikhailov, MD24
1 Emory Winship Cancer Institute, Atlanta, Georgia, United States
2 Emory Winship Cancer Institute, Atlanta, Georgia, United States
3 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
4 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
5 University of Cincinnati, Cincinnati, Ohio, United States
6 The Alfred-Haematology, Melbourne CBD, Victoria, Australia
7 ChemDiv Inc, San Diego, California, United States
8 Leningrad Regional Clinical Hospital, Leningrad, Russian Federation
9 Lomond Therapeutics, Dover, Delaware, United States
10 Lomond Therapeutics, Dover, Delaware, United States
11 Lomond Therapeutics, Dover, Delaware, United States
12 ChemDiv Inc, San Diego, California, United States
13 University of Cincinnati, Cincinnati, Ohio, United States
14 University Of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
15 ChemDiv Inc, San Diego, California, United States
16 State Budgetary Institution of Healthcare Moscow Multidisciplinary Clinical Center, Moscow, Russian Federation
17 Seoul National University Hospital, Seoul, Korea, Rep. of South
18 Taipei Medical University Shuang Ho Hospital - Clinical Research Center, Taipei, Taiwan
19 Linear Clinical Research, Joondalup, Australia
20 Lomond Therapeutics, Dover, Delaware, United States
21 Lomond Therapeutics, Dover, Delaware, United States
22 Lomond Therapeutics, Dover, Delaware, United States
23 University Of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
24 S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Central Federal District, Russian Federation

Background. Lomonitinib is a novel, highly potent, selective pan-FLT3/ IRAK4 inhibitor developed using an advanced in silico modeling approach and optimized to avoid off-target effects commonly seen with approved FLT3 inhibitors. FLT3 mutations are the most common genomic alterations in AML, and several targeted inhibitors have been approved either as monotherapy (gilteritinib) or as combination agents with chemotherapy (quizartinib and midastaurin). In preclinical studies, lomonitinib had superior efficacy to gilteritinib in several resistant models of FLT3 mutated AML including those harboring the gatekeeper resistance mutation. Lomonitinib had an exceptional pre-clinical safety profile and was well tolerated across all doses in a Phase 1 healthy volunteer study. Observed target engagement assessed via FLT3 plasma inhibitory activity (PIA) in the healthy volunteer study led to initiation of this Phase 1 study in AML.

 

Methods. This open-label, multicenter, United States and global dose-escalation Phase I trial (NCT06366789) enrolled subjects who were aged ≥ 18 years with R/R AML. Enrollment required centrally confirmed FLT3 ITD or TKD mutation, adequate organ function, and lack of uncontrolled infection. Intra-patient dose escalation was allowed for patients with stable or progressive disease after specific cohorts cleared. Based on lomonintib’s extended half-life and safety profile demonstrated in a prior Phase 1 SAD study2, we utilized a Day 1 loading strategy to rapidly attain steady state, enabling faster therapeutic effect compared to other FLT3 inhibitors. This was followed by a maintenance dose on Days 2-28. All days of Cycles 2 - 28 were dosed at the assigned maintenance dose. Seven dose-escalation cohorts of a loading dose followed by maintenance dose (10, 20, 30, 40, 60, 80, and 120 mg per day) were evaluated to explore safety, clinical activity, and potential biomarkers of activity. Pharmacodynamic measurements included inhibition of FLT3-ITD phosphorylation using a modified plasma inhibition assay, next generation targeted sequencing and inflammatory cytokines including soluble interleukin-2 receptor alpha (sIL2RA), and soluble FLT3 ligand.

Results. As of June 30, 2026, a total of 34 FLT3-mutated mutated R/R AML patients received single agent lomonitinib over the range 10-120 mg once daily. The median age was 64 years (26 – 82); 18 patients (52.9%) were male and 16 (47.1%) were female, and median bone marrow blasts across all patients was 39% (2 - 98.2). The median number of prior therapies was 3.24 (1-9). Lomonitinib was well tolerated and no treatment-related non-hematologic SAEs, QTc prolongation, or treatment-related deaths were reported. Plasma exposures (Cmax and AUCt) at steady state generally increased in a dose-proportional manner for the maintenance doses of 10 to 80 mg QD (with PK for 120 mg pending). The mean plasma exposures achieved were predicted to be in the therapeutic range based on preclinical models.

Among evaluable patients (n = 32), the overall response rate (defined as CR, CRh, CRi, MLFS) was 28.1% across all cohorts and 58.3% at predicted effective doses (80 mg or 120 mg). Within the 80 and 120 mg (n = 12), the ORR was 50% (5/10) among patients previously treated with a FLT3 inhibitor and 100% (2/2) among FLT3 inhibitor-naïve patients. A total of 13 patients remain on treatment. One patient who entered the trial with relapsed AML after allogeneic stem cell transplant remains on treatment at 24+ cycles with durable stable disease, preserved hematopoiesis and no transfusion requirements. Reductions in bone marrow blast counts were observed across all doses of lomonitinib. Pharmacodynamic analyses demonstrated dose-dependent decreases in sIL2RA and increases in soluble FLT3 ligand, consistent with target engagement and antileukemic activity. Updated efficacy, pharmacokinetic, and biomarker data will be presented at the meeting.

Conclusion. Single-agent lomonitinib demonstrated a favorable safety profile and encouraging clinical activity in heavily pretreated patients with FLT3-mutated R/R AML, including patients previously treated with FLT3 inhibitors and venetoclax. Clinical responses increased with dose, supporting continued dose escalation to define the recommended Phase 2 dose. The combined safety, pharmacokinetic, pharmacodynamic, and efficacy data support the continued development of lomonitinib as both a single agent and in combination with other AML therapies.

Colin Vale, MD: No relevant conflicts of interest to declare.